IBDEI379 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,51087,1,4,0)
 ;;=4^K75.81
 ;;^UTILITY(U,$J,358.3,51087,2)
 ;;=^5008828
 ;;^UTILITY(U,$J,358.3,51088,0)
 ;;=K75.89^^193^2500^16
 ;;^UTILITY(U,$J,358.3,51088,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51088,1,3,0)
 ;;=3^Inflammatory Liver Disease,Oth Spec
 ;;^UTILITY(U,$J,358.3,51088,1,4,0)
 ;;=4^K75.89
 ;;^UTILITY(U,$J,358.3,51088,2)
 ;;=^5008829
 ;;^UTILITY(U,$J,358.3,51089,0)
 ;;=K76.4^^193^2500^21
 ;;^UTILITY(U,$J,358.3,51089,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51089,1,3,0)
 ;;=3^Peliosis Hepatis
 ;;^UTILITY(U,$J,358.3,51089,1,4,0)
 ;;=4^K76.4
 ;;^UTILITY(U,$J,358.3,51089,2)
 ;;=^91041
 ;;^UTILITY(U,$J,358.3,51090,0)
 ;;=K71.50^^193^2500^25
 ;;^UTILITY(U,$J,358.3,51090,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51090,1,3,0)
 ;;=3^Toxic Liver Disease w/ Chronic Active Hepatitis w/o Ascites
 ;;^UTILITY(U,$J,358.3,51090,1,4,0)
 ;;=4^K71.50
 ;;^UTILITY(U,$J,358.3,51090,2)
 ;;=^5008799
 ;;^UTILITY(U,$J,358.3,51091,0)
 ;;=K71.51^^193^2500^26
 ;;^UTILITY(U,$J,358.3,51091,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51091,1,3,0)
 ;;=3^Toxic Liver Disease w/ Chronic Active Hepatitis w/ Ascites
 ;;^UTILITY(U,$J,358.3,51091,1,4,0)
 ;;=4^K71.51
 ;;^UTILITY(U,$J,358.3,51091,2)
 ;;=^5008800
 ;;^UTILITY(U,$J,358.3,51092,0)
 ;;=K71.7^^193^2500^29
 ;;^UTILITY(U,$J,358.3,51092,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51092,1,3,0)
 ;;=3^Toxic Liver Disease w/ Fibrosis & Cirrhosis of Liver
 ;;^UTILITY(U,$J,358.3,51092,1,4,0)
 ;;=4^K71.7
 ;;^UTILITY(U,$J,358.3,51092,2)
 ;;=^5008802
 ;;^UTILITY(U,$J,358.3,51093,0)
 ;;=K71.8^^193^2500^33
 ;;^UTILITY(U,$J,358.3,51093,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51093,1,3,0)
 ;;=3^Toxic Liver Disease w/ Oth Disorders of Liver
 ;;^UTILITY(U,$J,358.3,51093,1,4,0)
 ;;=4^K71.8
 ;;^UTILITY(U,$J,358.3,51093,2)
 ;;=^5008803
 ;;^UTILITY(U,$J,358.3,51094,0)
 ;;=K71.9^^193^2500^34
 ;;^UTILITY(U,$J,358.3,51094,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51094,1,3,0)
 ;;=3^Toxic Liver Disease,Unspec
 ;;^UTILITY(U,$J,358.3,51094,1,4,0)
 ;;=4^K71.9
 ;;^UTILITY(U,$J,358.3,51094,2)
 ;;=^5008804
 ;;^UTILITY(U,$J,358.3,51095,0)
 ;;=K75.2^^193^2500^20
 ;;^UTILITY(U,$J,358.3,51095,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51095,1,3,0)
 ;;=3^Nonspecific Reactive Hepatitis
 ;;^UTILITY(U,$J,358.3,51095,1,4,0)
 ;;=4^K75.2
 ;;^UTILITY(U,$J,358.3,51095,2)
 ;;=^5008826
 ;;^UTILITY(U,$J,358.3,51096,0)
 ;;=K75.3^^193^2500^13
 ;;^UTILITY(U,$J,358.3,51096,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51096,1,3,0)
 ;;=3^Granulomatous Hepatitis NEC
 ;;^UTILITY(U,$J,358.3,51096,1,4,0)
 ;;=4^K75.3
 ;;^UTILITY(U,$J,358.3,51096,2)
 ;;=^5008827
 ;;^UTILITY(U,$J,358.3,51097,0)
 ;;=K76.6^^193^2500^22
 ;;^UTILITY(U,$J,358.3,51097,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51097,1,3,0)
 ;;=3^Portal Hypertension
 ;;^UTILITY(U,$J,358.3,51097,1,4,0)
 ;;=4^K76.6
 ;;^UTILITY(U,$J,358.3,51097,2)
 ;;=^5008834
 ;;^UTILITY(U,$J,358.3,51098,0)
 ;;=F20.3^^193^2501^31
 ;;^UTILITY(U,$J,358.3,51098,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51098,1,3,0)
 ;;=3^Undifferentiated/Atypical Schizophrenia
 ;;^UTILITY(U,$J,358.3,51098,1,4,0)
 ;;=4^F20.3
 ;;^UTILITY(U,$J,358.3,51098,2)
 ;;=^5003472
 ;;^UTILITY(U,$J,358.3,51099,0)
 ;;=F20.9^^193^2501^27
 ;;^UTILITY(U,$J,358.3,51099,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51099,1,3,0)
 ;;=3^Schizophrenia,Unspec
 ;;^UTILITY(U,$J,358.3,51099,1,4,0)
 ;;=4^F20.9
